We are live on ! Find out more
Citadel Advisors

Citadel Advisors Portfolio holdings

AUM $875B
1-Year Est. Return 40.91%
 

Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.

This Fund
S&P 500
This Quarter Est. Return
-13.42%
1 Year Est. Return
+40.91%
3 Year Est. Return
+115.85%
5 Year Est. Return
+132.1%
10 Year Est. Return
+518.81%
AUM
$390B
AUM Growth
-$94.7B
Cap. Flow
+$10.4B
Cap. Flow %
2.66%
Top 10 Hldgs %
28.21%
Holding
14,957
New
1,520
Increased
5,503
Reduced
5,522
Closed
2,191

Sector Composition

Rank Sector Weight
1 Healthcare 2.83%
2 Technology 2.79%
3 Financials 2.29%
4 Consumer Discretionary 1.93%
5 Industrials 1.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ABX
10976
Abacus Global Management
ABX
$907M
$136K ﹤0.01%
13,647
-79,398
-85% -$790K
LCUT icon
10977
PUT
Lifetime Brands
LCUT
$226M
$136K ﹤0.01%
+12,300
New +$145K
SLN
10978
Silence Therapeutics
SLN
$648M
$136K ﹤0.01%
+11,441
New +$139K
STGW icon
10979
Stagwell
STGW
$2.23B
$136K ﹤0.01%
25,061
-169,361
-87% -$1.2M
SVIX icon
10980
-1x Short VIX Futures ETF
SVIX
$173M
$136K ﹤0.01%
+13,108
New +$151K
XERS icon
10981
Xeris Biopharma Holdings
XERS
$1.57B
$136K ﹤0.01%
88,323
-54,891
-38% -$116K
MDVL
10982
CALL
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$136K ﹤0.01%
+1,774
New +$156K
WLTH
10983
DELISTED
LifeGoal Wealth Builder ETF
WLTH
$136K ﹤0.01%
+16,290
New +$143K
ANGH icon
10984
Anghami
ANGH
$31.9M
$135K ﹤0.01%
+2,905
New +$219K
BHAT
10985
DELISTED
Blue Hat Interactive Entertainment Technology
BHAT
$135K ﹤0.01%
+9
New +$122K
CDZI icon
10986
Cadiz
CDZI
$294M
$135K ﹤0.01%
+57,690
New +$120K
VIP
10987
Vulcan Infrastructure and Power
VIP
$33.4M
$135K ﹤0.01%
5,300
+620
+13% +$34.9K
GYRE icon
10988
Gyre Therapeutics
GYRE
$708M
$135K ﹤0.01%
+10,117
New +$67.2K
IMNM icon
10989
CALL
Immunome
IMNM
$3.09B
$135K ﹤0.01%
42,100
+6,600
+19% +$24K
RCEL icon
10990
CALL
Avita Medical
RCEL
$243M
$135K ﹤0.01%
28,400
+1,500
+6% +$9.27K
VANI icon
10991
Vivani Medical
VANI
$126M
$135K ﹤0.01%
22,204
+14,906
+204% +$80.4K
ADERU
10992
DELISTED
26 Capital Acquisition Corp Unit
ADERU
$135K ﹤0.01%
13,269
-800
-6% -$8.05K
PNTM.WS
10993
DELISTED
Pontem Corporation Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
PNTM.WS
$135K ﹤0.01%
1,018,754
-489
-0% -$108
WPCB.WS
10994
DELISTED
Warburg Pincus Capital Corporation I-B Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
WPCB.WS
$135K ﹤0.01%
500,372
-59,627
-11% -$24.4K
CPRX
10995
PUT
DELISTED
Catalyst Pharmaceutical
CPRX
$134K ﹤0.01%
19,100
-800
-4% -$5.87K
CSBR icon
10996
Champions Oncology
CSBR
$70.4M
$134K ﹤0.01%
16,597
+518
+3% +$3.96K
ISSC icon
10997
Innovative Solutions & Support
ISSC
$412M
$134K ﹤0.01%
+18,572
New +$148K
NRXP icon
10998
CALL
NRX Pharmaceuticals
NRXP
$140M
$134K ﹤0.01%
22,270
-6,810
-23% -$89.5K
FTH
10999
Faeth Therapeutics
FTH
$836M
$134K ﹤0.01%
+2,969
New +$111K
TTMI icon
11000
CALL
TTM Technologies
TTMI
$14.7B
$134K ﹤0.01%
+10,700
New +$148K

Similar funds

Citadel Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Citadel Advisors held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Citadel Advisors's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.

By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.

  • Citadel Advisors's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
  • Citadel Advisors added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
  • Citadel Advisors's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
  • Citadel Advisors fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
  • Citadel Advisors's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
  • Citadel Advisors opened 1,520 new positions and closed 2,191 in Q2 2022.
  • Citadel Advisors's portfolio value fell 20% quarter-over-quarter to $390B.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.